What to expect: side effects when switching from Mounjaro to Wegovy

The real decision: are you switching because of side effects, or despite them?

People arrive at this crossroads for very different reasons. Some switch from Mounjaro to Wegovy because their current GI side effects feel unmanageable and they've been told semaglutide may sit more gently with some patients. Others are moving from Wegovy to Mounjaro and find themselves wondering whether a second round of nausea awaits. Both are legitimate concerns, and neither instinct is wrong. What matters is understanding what actually happens biologically when you move between these two medicines, and setting realistic expectations before the first new injection.

The misconception worth letting go is that switching mid-treatment means starting entirely from scratch. Clinically, there is overlap: both medicines slow gastric emptying and act on appetite pathways, which means some of what your body learned to tolerate on one may carry over. But the overlap is not complete, and your prescriber will factor in where you are in your current titration before recommending a starting dose for the new medicine. The safety considerations behind switching are worth reading in full if you haven't already.

The framing that helps most: think of this as a decision with two distinct arms. First, why you're switching. Second, how prepared you are for the adjustment phase. Our prescribers work through both with you.

What the side-effect profile looks like in the adjustment period

Both tirzepatide and semaglutide share a GI-led side-effect profile. Nausea, loose stools, constipation, indigestion, burping and fatigue are common to both, and they tend to peak in the first days after starting or increasing a dose. When you switch medicines, you are (in pharmacological terms) introducing a new molecule to receptors that have been calibrated for a different one. That is usually enough to trigger a fresh adjustment phase, even if your previous side effects had fully settled.

The difference in receptor action is relevant here. Mounjaro's dual GIP and GLP-1 agonism produces a side-effect signature that includes slightly higher rates of nausea and vomiting at the initiation phase in some patients, according to SmPC data. Semaglutide's single GLP-1 pathway has its own profile; for some people the gastrointestinal burden feels different in character, even when severity is similar. Neither medicine is categorically easier, individual response varies considerably. If you want a thorough breakdown before making any decision, the detailed comparison of Wegovy and Mounjaro side effects sets out what the evidence shows for each medicine. The NHS medicines pages for both tirzepatide and semaglutide set out the full side-effect lists and when to seek urgent help, and they are worth bookmarking before you switch.

One specific point on the side effects of moving from Mounjaro to Wegovy: because Wegovy's titration starts lower, some patients switching from a mid-to-high Mounjaro dose find the initial Wegovy dose feels comparatively mild. That can be reassuring, but it doesn't mean the later dose increases won't bring their own adjustment. Expect the staircase, not a single step.

A direct comparison: what the evidence says about each medicine's side-effect pattern

The table below draws on published SmPC data and the SURMOUNT-1 and STEP 1 trial results, both published in the New England Journal of Medicine. Direct head-to-head side-effect data from SURMOUNT-5 is limited, as that trial focused on weight outcomes rather than adverse-event comparison, but the broader evidence base gives a clear picture.

The contraception point is one many patients miss: if you are taking an oral contraceptive and switching to Mounjaro, MHRA guidance (reflected in NHS England's weight-management injections guidance) recommends adding a non-oral method for the first four weeks of treatment and after each subsequent dose increase. Moving in the other direction, to Wegovy, this specific requirement does not apply, but always confirm your full medicines list with your prescriber.

Factors your prescriber weighs before recommending a switch

The broader Wegovy versus Mounjaro comparison covers efficacy at length. Here the focus is narrower: what makes a switch clinically appropriate, and how that connects to what you experience afterwards.

Your prescriber will look at how far into your current titration you are, what your weight response has been, whether your side effects are a reason to switch or can be managed with timing and dietary adjustments, and what your underlying conditions suggest about which mechanism suits you better. Someone with well-controlled type 2 diabetes, for instance, has different considerations from someone managing obesity with no metabolic comorbidities. Those factors don't disappear when a medicine changes.

The experience of changing from Mounjaro to Wegovy is also shaped by timing: switching during a settled phase, rather than mid-escalation, typically produces a smoother adjustment. Your prescriber can advise on the safest moment in your current schedule to make the move. For a full side-by-side look at how these medicines compare on adverse events, the Wegovy and Mounjaro side-effect comparison page goes deeper into the published data.

Which medicine suits you is a clinical decision our prescribers make with you, not one to reach from a comparison table alone. If you're ready to have that conversation, check your eligibility and start your free consultation.